NSPR Strangle Strategy

NSPR (InspireMD, Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

NSPR (InspireMD, Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $54.9M, a beta of 0.82 versus the broader market, a 52-week range of 1.02-2.93, average daily share volume of 254K, a public-listing history dating back to 2011, approximately 85 full-time employees. These structural characteristics shape how NSPR stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.82 places NSPR roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a strangle on NSPR?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current NSPR snapshot

As of May 15, 2026, spot at $1.10, ATM IV 20.40%, IV rank 0.70%, expected move 5.85%. The strangle on NSPR below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on NSPR specifically: NSPR IV at 20.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a NSPR strangle, with a market-implied 1-standard-deviation move of approximately 5.85% (roughly $0.06 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NSPR expiries trade a higher absolute premium for lower per-day decay. Position sizing on NSPR should anchor to the underlying notional of $1.10 per share and to the trader's directional view on NSPR stock.

NSPR strangle setup

The NSPR strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NSPR near $1.10, the first option leg uses a $1.16 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NSPR chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NSPR shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$1.16	N/A
Buy 1	Put	$1.05	N/A

NSPR strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

NSPR strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on NSPR. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on NSPR

Strangles on NSPR are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NSPR chain.

NSPR thesis for this strangle

The market-implied 1-standard-deviation range for NSPR extends from approximately $1.04 on the downside to $1.16 on the upside. A NSPR long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current NSPR IV rank near 0.70% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on NSPR at 20.40%. As a Healthcare name, NSPR options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NSPR-specific events.

NSPR strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NSPR positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NSPR alongside the broader basket even when NSPR-specific fundamentals are unchanged. Always rebuild the position from current NSPR chain quotes before placing a trade.

Frequently asked questions

What is a strangle on NSPR?: A strangle on NSPR is the strangle strategy applied to NSPR (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With NSPR stock trading near $1.10, the strikes shown on this page are snapped to the nearest listed NSPR chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are NSPR strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the NSPR strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 20.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a NSPR strangle?: The breakeven for the NSPR strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NSPR market-implied 1-standard-deviation expected move is approximately 5.85%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on NSPR?: Strangles on NSPR are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NSPR chain.
How does current NSPR implied volatility affect this strangle?: NSPR ATM IV is at 20.40% with IV rank near 0.70%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.